Alteraciones en el sistema urinario por Adalimumab y Golimumab reportados al Programa Distrital de Farmacovigilancia en Bogotá durante el periodo comprendido entre el 2012 al 2016

The present study aims to characterize and analyze the alterations of the urinary system by Adalimumab and Golimumab reported to the district pharmacovigilance program of Bogotá D.C during 2012 to 2016. We showed 120 reports by Adalimumab and 26 by Golimumab. The alterations were characterized and as a result of the determination in the frequency of these, it was found that urinary tract infections had the highest number of reported cases was 106 cases equivalent to (73%) of the total reports for the two drugs; Likewise; A causality analysis was carried out by means of an evaluation of the causality criteria of Uppsala, for which a total of 114 reports of possible causality were presented, corresponding to (78%) of the 146 reports. On the other hand, the gender behavior shows that they are present more frequently in women, Adalimumab (77%) and Golimumab (96%) corresponding to an age range of 30 to 79 years, where the level of seriousness Which was determined in large part of the reports was of a moderate type requiring suspension of the drugs and pharmacological treatment to treat the alterations presented. As for the type of ADRs presented were type A, B and C, with Type A being equivalent to (77%) given that these have a close relationship with the mechanism of action of the drugs. Finally, we conclude that a benefit risk analysis of immunosuppressive-type biological therapies, training of the appropriate staff, and access to the medical histories are required

• Autores: Mendoza Londoño, Luis Alberto; Triviño Lara, Sarai
• Tipo de recurso: Trabajo de grado de pregrado
• Fecha de publicación: 2017
• Institución: Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
• Repositorio: Repositorio Institucional UDCA
• Idioma: spa
• OAI Identifier: oai:repository.udca.edu.co:11158/703
• Acceso en línea: https://repository.udca.edu.co/handle/11158/703
• Palabra clave: Alteraciones del sistema urinario; Reaccciones adversas a medicamentos; Tratamiento biológico; Iinmunosupresores; Programa Distrital de Farmacovigilancia -- Bogotá (Colombia); Adalimumab -- Efectos secundarios; Golimumab -- Efectos secundarios
• Rights: closedAccess
• License: Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales